This webpage contains promotional information regarding Napp products. The content has been reviewed ny Napp to ensure compliance with the ABPI code of practice for the pharmaseutical industry.
For study results with respect to combination of therapies, effect on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1 of the SmPC.1
For the treatment of DKD in adults with T2DM as add-on to standard of care, a dose of 100 mg once-daily should be used.1
See SmPC Section 4.2 for dosing details
|What to do if tighter glycaemic control
|eGFR ≥60||Use Invokana 300 mg rather than 100 mg|
|eGFR <60||Consider adding another anti-hyperglycaemic agent|
DKD: Diabetic Kidney Disease; eGFR: estimated Glomerular Filtration Rate; SmPC: Summary of Product Characteristics; T2DM: Type 2 Diabetes Mellitus; UACR: Urinary Albumin/ Creatinine Ratio.